Distinct subtypes of serous ovarian carcinoma identified by p53 determination☆
- 31 December 2003
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 91 (3), 504-512
- https://doi.org/10.1016/j.ygyno.2003.08.034
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Comparison of Serous and Mucinous Ovarian Carcinomas: Distinct Pattern of Allelic Loss at Distal 8p and Expression of Transcription Factor GATA-4Laboratory Investigation, 2001
- p53 and bcl-2 in Epithelial Ovarian Carcinoma: Their Value as Prognostic Indicators at a Median Follow-up of 60 MonthsGynecologic Oncology, 2000
- Clinical Significance of Apoptosis-Related Factors p53, Mdm2, and Bcl-2 in Advanced Ovarian CancerJournal of Clinical Oncology, 1999
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998
- p53 overexpression is Not an independent prognostic factor for patients with primary ovarian epithelial cancerCancer, 1997
- Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomasBritish Journal of Cancer, 1997
- Differences in Risk Factors for Epithelial Ovarian Cancer by Histologic Type: Results of a Case-Control StudyAmerican Journal of Epidemiology, 1996
- p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial overian carcinomaCancer, 1995
- NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian CancerJAMA, 1995
- The Prognostic Significance of Residual Disease, FIGO Substage, Tumor Histology, and Grade in Patients with FIGO Stage III Ovarian CancerGynecologic Oncology, 1995